Industry pundits talk about conversational AI for sales reps, the arrival of AI agents, a potential overhaul in the SaaS market for pharma enterprises and the tricky arena of influencer engagement in this instalment on key trends playing out on the tech front and in India. Expanding healthcare coverage is also improving the outlook for pharma in the country, they said.
AI is rescripting norms around customer engagement, personalization, and efficiency, opening up a range of opportunities for pharma in the marketing arena, albeit with appropriate guardrails.
There’s also no denying the role of social media influencers and their army of followers as they shape opinions and...
Create an account to read this article
Already a subscriber?
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.
Sarepta is in a cash crunch with sales of Elevidys slumping due to safety concerns and with financial commitments coming due, including debt repayments and milestone fees for its partner Arrowhead.
Plus deals involving Basilea/Venatorx, CorMedix/Melinta, SERB/Y-mAbs, XOMA/Lava, XOMA/Hillevax, MaxCyte/Adicet/Anocca and Bausch Health/DURECT.
The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.
